Not losing much weight on Mounjaro — what's actually going on

The myth that Mounjaro produces fast, steady loss from day one

The biggest misconception among people who feel they're not losing much weight on Mounjaro is that the medicine should produce visible results almost immediately. In reality, the earliest weeks are primarily about your body adjusting to tirzepatide, the first pen's job is to reduce side effects, not to deliver maximum appetite suppression. The 2.5 mg dose is lower than any therapeutic maintenance dose in the licensed schedule, so the appetite-dampening effect at that stage is modest by design.

Progress typically becomes more noticeable from the second or third dose increase onward. In the SURMOUNT-1 trial, average weight reduction at higher doses reached around 20–21% over 72 weeks, but that trajectory was gradual, not a straight line from week one. Comparing your first-month experience against a 72-week average is one of the most common reasons people reach the wrong conclusion about whether Mounjaro is working for them. If you want a clearer sense of the expected timeline, the Mounjaro timeline guide on this site covers what to expect at each stage.

It's worth saying plainly: if you're reading this feeling quietly frustrated, perhaps after watching someone else's progress and wondering what you're doing wrong, that feeling is genuinely common. Weight loss is rarely linear, and the gap between expectation and reality in the early months catches a lot of people off guard.

What actually slows progress, and why it isn't always the medicine

Several things can suppress the number on the scales even when tirzepatide is doing its job at a biological level. Fluid retention (which can shift by a kilogram or two depending on salt intake, menstrual cycle, or a period of higher carbohydrate eating) is frequently mistaken for stalled fat loss. Muscle gain from increased activity, though a positive outcome, adds mass that offsets fat reduction on a standard scale.

Calorie compensation is a subtler issue. Mounjaro slows gastric emptying and reduces appetite through dual GIP and GLP-1 receptor activity, as the NHS tirzepatide medicines page explains. But if portion sizes haven't changed much, or if the foods being eaten are energy-dense even in smaller amounts, the calorie reduction may be smaller than expected. Sleep quality and chronic stress both affect cortisol, which in turn affects where and how the body stores fat, factors the medicine can't fully counteract on its own.

This doesn't mean effort is the problem; it means the medicine works within a system, not instead of one. For a broader look at what influences results, the Mounjaro treatment overview covers the evidence in full.

When slower-than-expected progress is a signal worth investigating

There are situations where slow progress genuinely does warrant clinical review rather than patience. If you have been on a stable maintenance dose for two or more months and weight has not shifted by at least a few percent, that is worth raising with your prescriber. The same applies if you were losing steadily and have hit a clear plateau lasting six weeks or more.

Thyroid function is one of the first things a clinician might consider, since an underactive thyroid slows metabolism independently of appetite. Certain medications (including some antidepressants, corticosteroids, and antipsychotics) can blunt the effect of weight-loss treatment. Neither of these is a reason to stop Mounjaro; both are reasons to have the conversation. You can also read about what to consider when Mounjaro isn't producing results for a more detailed breakdown of these clinical factors.

NICE's guidance on tirzepatide (TA1026) notes that continuing treatment should be reviewed if weight loss is less than 5% after six months at the highest tolerated dose, a threshold worth knowing, but one that a prescriber applies in context, not mechanically. If you're currently taking Mounjaro and the scales haven't moved despite sticking to the plan, this guide for people on Mounjaro who aren't losing weight walks through the most likely reasons and what to do next. See the full NICE tirzepatide appraisal for the recommendation detail.

For context on how Mounjaro is priced privately, the Mounjaro cost page breaks down what is typically included across different providers.

What a clinical review of your progress actually looks like

A prescriber looking at slow progress on Mounjaro isn't simply deciding whether to increase the dose. They're looking at the whole picture: how long you've been on each dose, what other medicines you take, whether there's an underlying condition that could explain the plateau, and whether the dose you're on has had enough time to show its effect. Dose changes on tirzepatide are made in a minimum four-week rhythm, and jumping ahead doesn't accelerate results, it increases the risk of side effects that can themselves make it harder to eat well. If the plateau has been going on for a while and you're uncertain whether to push on or seek a review, our page on not losing any weight on Mounjaro covers the scenarios where waiting is reasonable and the ones where it isn't.

At nume, every repeat order involves a clinical re-review by a GPhC-registered prescriber (a real clinician, not an automated system) before anything is dispatched. That review is the right moment to raise concerns about your rate of progress. If you have specific questions between orders, our support team is available seven days a week.

If you'd like a prescriber to look at where you are and what might help, you can speak to our prescribers through a free consultation, no waiting list, same-day clinical review for consultations submitted before noon.